linjc16/ctgov huggingface dataset:
Effects of Physical Exercise to Prevent Osteoporosis in Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
According to the World Health Organization criteria, osteoporosis was defined as a bone mineral density that lies 2.5 standard deviations or more below the average value for young healthy women. Osteoporosis is a major cause of fractures and can lead to serious complications in postmenopausal women. For this reason, approaches to prevent the appearance and progression of osteoporosis are of primary importance. This randomized clinical trial analyzes the effects of two types of physical exercise oriented to prevent osteoporosis in postmenopausal women with pharmacological supplements of Calcium and Vitamin-D.

Official Title
-----------------
Efecto de Dos Tipos de Ejercicio físico Para Prevenir la Osteoporosis en Mujeres Postmenopausicas, un Ensayo Clinico Aleatorizado

Conditions
-----------------
Osteoporosis, Postmenopausal, Osteoporosis, Osteopenia, Physical Activity

Intervention / Treatment
-----------------
* Other: walking at an intense pace
* Other: osteoporosis specific-oriented training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal woman Pharmacological treatment (VitaminD+Calcium) Exclusion Criteria: Disease or physical-mental condition which prevents to perform the proposed physical exercise
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Control<br>walking at an intense pace | Other: walking at an intense pace<br>* Participants walk 6 kilometers in 1 hour at least 3 times per week<br>|
| Experimental: Experimental<br>osteoporosis specific-oriented training | Other: osteoporosis specific-oriented training<br>* 1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Femoral neck T-score | The score compares femoral neck bone mineral density to a reference mean | Change from baseline score at two years | 
| Lumbar spine T-score | The score compares lumbar spine bone mineral density to a reference mean | Change from baseline score at two years |
Correlation Between Minimum Inhibitory Concentration and Clinical Outcome of Invasive Fusariosis

Study Overview
=================
Brief Summary
-----------------
Multi-centered, international, observational and retrospective study to analyze the correlation between MIC and clinical outcome in patients with invasive fusariosis.

Official Title
-----------------
Correlation Between Minimum Inhibitory Concentration and Clinical Outcome of Invasive Fusariosis

Conditions
-----------------
Invasive Fusariosis

Intervention / Treatment
-----------------
* Other: There is no intervention. This is an observational study.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Invasive fusariosis diagnostic Proof of anti-fungic susceptibility according to EUCAST or CLSI, for the medicine used in the treatment of invasive fusariosis. Available data about anti-fungic medicines used: name of medicine, start and end date of treatment. Available information about clinical outcome of illness after 30 days, 6 weeks and 90 days (dead or alive). Only cases of invasive fusariosis proven or possible will be included. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Invasive Fusariosis<br>Patients hospitalized with an invasive fusariosis diagnostic in the stablished period of study. | Other: There is no intervention. This is an observational study.<br>* There is no intervention. This is an observational study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Evolution | Retrospective evaluation of death rate. | 6 weeks after diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
invasive fusariosis, minimum inhibitory concentration
Clinical Performance of Extended Wear Silicone Hydrogel Lenses

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to investigate the clinical performance of a new silicone hydrogel contact lens over a period of 6 months of extended wear.

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Device: Silicone hydrogel contact lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is correctable to at least 6/9 distance visual acuity in each eye with spherical contact lenses. Is a current daily wear soft contact lens wearer. Has no clinically significant anterior eye findings. Has no other active ocular disease. Exclusion Criteria: Has any systemic disease that might interfere with contact lens wear Is using any systemic or topical medications that will affect ocular health. Has any pre-existing ocular irritation that would preclude contact lens fitting. Has any ocular pathology or severe insufficiency of lacrimal secretion (dry eyes) that would affect the wearing of contact lenses. Has undergone corneal refractive surgery. Is pregnant, lactating or planning a pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Silicone hydrogel contact lens|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Multi-omics Study of Epithelial Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.

Official Title
-----------------
A Multi-omics Study on the Invasiveness of Epithelial Ovarian Cancer

Conditions
-----------------
Epithelial Ovarian Cancer, Tumor Invasiveness, Whole Exome Sequencing, Transcriptomics, Metabolomics, Tumorigenesis

Intervention / Treatment
-----------------
* Combination Product: A multi-omics analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed primary epithelial ovarian cancer Signed an approved informed consents Feasible for biopsy Exclusion Criteria: Not meeting all of the inclusion criteria
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Combination Product: A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequencies of somatic driving mutations | The differences of frequencies of somatic driving mutations will be compared between patients of different FIGO stages and different pathological subtypes. | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequencies of alteration of RNA expression | The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients of different FIGO stages and different pathological subtypes. | Two years | 
| Frequencies of alteration of protein expression and signal pathway | The alteration of patterns of protein expression and signal pathway will be compared between patients of different FIGO stages and different pathological subtypes. | Two years | 
| Progression-free survival | Progression-free survival between patients with differential expressed multi-omics will be compared. | Five years |
Screening and Treatment of SAHS in Patients With Acute Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
Ischemic stroke is a kind of common disease with great harm. In acute stage of stroke there is sharply increasing morbidity of sleep apnea hypopnea syndrome. Our suppose that treatment with noninvasive ventilation for patients with acute ischemic stroke should improve the functional prognosis（measuring with 90d modified Rankin score）.

Detailed Description
-----------------
In acute state of ischemic stroke，if patients with sleep apnea hypopnea syndrome may need additional respiratory management such bi-level positive airway pressure.We supposed the patients with stroke can take benefit of functional recovery form bi-level positive airway pressure. We choose the patients who suffered ischemic stroke in 48 hours ，then evaluate the respiratory status. Stroke patients who were diagnosed as sleep apnea hypopnea syndrome will accept additional treatment with bi-level positive airway pressure for 7 night（per night 6 hours）.Then the modified Rankin scale score and NIHSS will be recorded at 30 days and 90 days after stroke.

Official Title
-----------------
Screening and Treatment of in Sleep Apnea Hypopnea Syndrome（SAHS)Patients With Acute Ischemic Stroke

Conditions
-----------------
Ischemic Stroke, Sleep Apnea Syndrome

Intervention / Treatment
-----------------
* Device: Bi level positive pressure ventilation
* Device: bi-level positive airway pressure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ischeic stroke onset within 48 hours , NIHSS:4-15 Exclusion Criteria: mRs>2 before onset of enrollment severe hepatic renal insufficiency cancer in reached an advanced stage

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: bi-level positive airway pressure<br>bi-level positive airway pressure for 6 hour per night，total 7 days | Device: Bi level positive pressure ventilation<br>* Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.<br>Device: bi-level positive airway pressure<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Rankin Scale score | 0-2 Modified Rankin Scale score should be recognized good functional prognosis | 90 days after symptoms | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stroke, SAHS, BiPAP
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4

Study Overview
=================
Brief Summary
-----------------
The Hemolytic Uremic Syndrome (HUS) in its typical form occurs after a food born infection with a shiga-toxin secreting bacteria, usually Escherichia coli of the O157H7 serotype. An outbreak of bloody diarrhea followed by HUS begun after a collective meal with 120 persons on June 8th, 2011 in Bègles, a city of Bordeaux urban area (CUB). At least 9 patients, 8 adults and 1 child have been involved in this HUS outbreak, E. coli of the O104:H4 serotype being demonstrated in most patients. This outbreak is remarkable by its preponderance in adults and women, its aggressiveness with multiorgan involvement , i.e. the kidneys, brain, liver, pancreas, and skin. Pathophysiology, prognosis, and treatment of typical HUS are poorly defined, particularly in adults who are usually not involved in typical E. coli O157H7 HUS. The aim of the present study is to gain knowledge on these different aspects of the HUS, including response to therapy.

Official Title
-----------------
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 in Bordeaux Urban Area, June 2011: Evaluation of Diagnostic, Prognostic and Pathophysiological Data

Conditions
-----------------
Hemolytic-uremic Syndrome, Escherichia Coli Infections

Intervention / Treatment
-----------------
* Other: HUS standard coverage care (including in ICU)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with HUS concomitant to the outbreak linked to E. coli O104:H4 Exclusion Criteria: Patient not willing to participate or to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HUS epidemy in Bordeaux, E. coli of the O104H4 serotype<br> | Other: HUS standard coverage care (including in ICU)<br>* HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improve scientific knowledge on epidemic HUS in the context of an outbreak of E. coli O104:H4 HUS in the town of Bègles, urban area of Bordeaux, France | This is an observational propspective study in which all data will be collected on all pertinent aspects of disease, including therapeutic regimens. | during patient hospitalization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate efficiency of therapeutic and diagnostic strategies |  | during patient hospitalization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemolytic-uremic syndrome, shiga-toxin-producing E. Coli
Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
Autologous platelet-secreted growth factors (GFs) may have therapeutic effects in osteoarthritis (OA) capsular joints via multiple mechanisms. The aim is to examine the effect of a platelet-derived preparation rich in growth factors (PRGFs) in OA of the knee.

Detailed Description
-----------------
Autologous platelet-secreted growth factors (GFs) may have therapeutic effects in osteoarthritis (OA) capsular joints via multiple mechanisms. The investigators aim is to examine the effect of a platelet-derived preparation rich in growth factors(PRGFs) in OA of the knee, using parameters of pain, function, quality of life and safety.

Official Title
-----------------
Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis - A Randomized-Double-Blind Trial

Conditions
-----------------
Osteoarthritis of the Knee

Intervention / Treatment
-----------------
* Biological: Platelet Rich Plasma (Preparation Rich in Growth Factors)
* Drug: Hyaluronic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 40-75 years old diagnosed Oa of the knee more then 1 year no knee deformation Exclusion Criteria: mental of physical disabilities pregnancy deformities of the knee

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Platelet Rich Plasma (Preparation Rich in Growth Factors)<br>intra articular injection 6ml of platelet-derived preparation rich in growth factors | Biological: Platelet Rich Plasma (Preparation Rich in Growth Factors)<br>* intra articular injection 6ml<br>* Other names: Platelet-derived preparation rich in growth factors;|
| Active Comparator: Hyaluronic acid<br>Drug: hyaluronic acid 20 mg / 2 ml Other Name: Arthrease | Biological: Platelet Rich Plasma (Preparation Rich in Growth Factors)<br>* intra articular injection 6ml<br>* Other names: Platelet-derived preparation rich in growth factors;Drug: Hyaluronic acid<br>* Intra articular injections: 20 mg / 2 ml<br>* Other names: Arthrease;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in pain, function, quality of life and activity level in knee osteoarthritis | Improvement in pain, function, quality of life, activity level - using scores adapted to measure these parameters in knee osteoarthritis. | 1 -2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PRP, Osteoarthritis, PRGF, Hyaluronic acid
Hunger, Satiety, and Metabolic Responses to High-fat Meals of Varying Fatty Acid Composition

Study Overview
=================
Brief Summary
-----------------
This study evaluates the effects of dietary fatty acid composition from high fat meals on markers of hunger, satiety and metabolism.

Official Title
-----------------
Hunger, Satiety, and Metabolic Responses to High-fat Meals of Varying Fatty Acid Composition

Conditions
-----------------
Body Weight Changes

Intervention / Treatment
-----------------
* Other: MUFA-rich HF Meal
* Other: PUFA-rich HF Meal
* Other: SFA-rich HF Meal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI of >18.5-24.9kg/m2 Woman 18-40yrs of age Exclusion Criteria: Evidence of weight loss or gain exceeding 5% of their body weight within the past 3 months. Plans to lose weight or begin a weight loss program between initiation of study and final testing. Plans to begin an exercise program or change current exercise routines between initiation of study and final testing. Is on a medically prescribed diet Does not consume breakfast regularly Rate less than 80% of foods offered in the buffet at 50mm or more on the 100mm VAS as palatable Medications that could influence appetite or sensory function Reports of metabolic or endocrine disease, gastrointestinal disorders, or history of medical or surgical events that could affect fat digestion and hormone signaling. Any chronic disease including type II diabetes, hypothyroidism, hyperthyroidism, cardiovascular disease, and cancer Any supplements that a subject begins taking between initiation of study and final testing. Anyone who is currently pregnant, lactating, or planning on becoming pregnant before the conclusion of this study. Anyone who has allergies to any of the components of the liquid meals Anyone who has donated blood in the last 20 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MUFA-rich HF Meal<br>High-fat meal rich in monounsaturated fatty acids | Other: MUFA-rich HF Meal<br> <br> |
| Experimental: PUFA-rich HF Meal<br>High-fat meal rich in polyunsaturated fatty acids | Other: PUFA-rich HF Meal<br> <br> |
| Experimental: SFA-rich HF Meal<br>High-fat meal rich in saturated fatty acids | Other: SFA-rich HF Meal<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peptide-YY |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analog Scale |  | 18 months |
Primary Care Obesity Prevention and Treatment

Study Overview
=================
Brief Summary
-----------------
The overall objective of this pilot is to demonstrate the feasibility of a low-cost intervention targeting obesity prevention among children in a primary care setting. Specifically, the investigators aim to answer the following questions: Can the investigators recruit and retain patients using the methods proposed, and how easy or difficult will this process be? Can physicians deliver the proposed intervention messages in the time the investigators have proposed? Can the phone counselor reach participants and accomplish the goals outlined for these calls? Can the investigators obtain the data proposed and within the proposed time frame?

Official Title
-----------------
Test the Feasibility of Primary Care Obesity Prevention and Treatment - Pilot Study

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: Healthy eating and physical activity
* Behavioral: Safety and injury prevention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: child BMI ≥ 70th percentile for age and sex according to CDC Growth Tables child scheduled for an upcoming well child visit

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy eating/physical activity<br> | Behavioral: Healthy eating and physical activity<br>* Parent counseling and coaching regarding healthy eating and physical activity habits for their child<br>|
| Active Comparator: Safety/Injury prevention<br> | Behavioral: Safety and injury prevention<br>* Parent counseling and coaching regarding general personal and household safety<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of recruiting and retaining families |  | Enrollment to 3-month followup | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Child weight (BMI) |  | Baseline and 3-months post | 
| Parental perceptions of child weight |  | Baseline and 3-months post intervention | 
| Satisfaction with intervention |  | 3-months post intervention |